Immune checkpoints provide broad and diverse opportunities to enhance T cell activity that can increase anti-tumor immunity, potentially resulting in durable clinical responses. GenScript has developed overexpression cell line products expressing the most popular co-inhibitory and co-stimulatory immune checkpoints of human, mouse and cynomolgus monkey origin to accelerate immunotherapy discovery and clinical translation.
Single Clone
Multiple Species
Guaranteed Performance
Stringent QC Standards
| Receptor | Cell Line | Cat.No. |
|---|---|---|
| PD-1 | CHO-K1/PD-1 | |
| CHO-K1/mouse PD-1 | ||
| CHO-K1/cyno PD-1 | ||
| Daudi/PD-1 | M00630 | |
| PD-L1 | HEK293/PD-L1 | M00544 |
| CHO-K1/PD-L1 | ||
| CHO-K1/mouse PD-L1 | ||
| CHO-K1/cyno PD-L1 New | M00573 | |
| PD-L2 | CHO-K1/PD-L2 | |
| CHO-K1/cyno PD-L2 | M00629 | |
| CTLA4 | CHO-K1/CTLA4 | |
| CHO-K1/mouse CTLA4 | ||
| CHO-K1/cyno CTLA4 | ||
| Lag3 | CHO-K1/Lag3 New | M00532 |
| TIGIT | CHO-K1/TIGIT | |
| CHO-K1/mouse TIGIT New | M00585 | |
| Tim3 | CHO-K1/Tim3 | |
| VISTA | CHO-K1/VISTA New | M00533 |
| CHO-K1/Mouse VISTA | M00633 | |
| CHO-K1/Cyno VISTA | M00634 | |
| BDCA2 | CHO-K1/BDCA2 | |
| CHO-K1/Cyno BDCA2 | ||
| CHO-K1/BDCA2 and FcER1G | ||
| CHO-K1/ Cyno BDCA2 and FcER1G | ||
| BTLA | CHO-K1/BTLA | |
| KIR | CHO-K1/KIR | M00650 |
| CD38 | CHO-K1/human CD38 | M00553 |
| CHO-K1/mouse CD38 | M00636 | |
| CD47 | CHO-K1/CD47 | |
| CHO-K1/Mouse CD47 | M00631 | |
| CHO-K1/Cyno CD47 | M00632 | |
| CD80 | CHO-K1/CD80 | M00545 |
| CD103 | CHO-K1/ITGAE | |
| CD112 | CHO-K1/CD112 | |
| CD155 | CHO-K1/CD155 | |
| CHO-K1/Cyno CD155 | ||
| CHO-K1/Mouse CD155 | ||
| CD200 R1 | CHO-K1/CD200 R1 |
Cell line product catalog including brief introductions, product list and validations.
Free DownloadCell line product catalog including brief introductions, product list and validations.
Free Download
